Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Ozempic, the Danish pharma giant Novo Nordisk's anti-diabetic drug, has had everyone's attention over the past year. The ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...